← Back to patent-cliff list
XY-0206
Tier C — Watch / tradeXY-0206
-
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：FLT3, VEGFR2
Indications (approved)：Acute myeloid leukaemia, Solid tumour
Regional status
US
-
EU
-
China
Phase III
2023-07-26
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of XY-0206?
Approved indications include: Acute myeloid leukaemia, Solid tumour.
When does the XY-0206 patent expire?
No public expiry year is available for XY-0206 yet; this page updates once verified.
How do I get a quote for XY-0206 intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-03